Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
71
REPL Quote, Financials, Valuation and Earnings
Last price:
$10.52
Seasonality move
:
-2.1%
Day range:
$10.03 - $10.56
52-week range:
$2.68 - $14.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.14x
Volume:
1.3M
Avg. volume:
2.5M
1-year change:
-20.05%
Market cap:
$826M
Revenue:
--
EPS (TTM):
-$3.61
Analysts' Opinion
-
Consensus RatingReplimune Group, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.57, Replimune Group, Inc. has an estimated upside of 19.39% from its current price of $10.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $10.53.
Fair Value
-
According to the consensus of 7 analysts, Replimune Group, Inc. has 19.39% upside to fair value with a price target of $12.57 per share.
REPL vs. S&P 500
-
Over the past 5 trading days, Replimune Group, Inc. has overperformed the S&P 500 by 4.55% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Replimune Group, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Replimune Group, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Replimune Group, Inc. reported revenues of --.
Earnings Growth
-
Replimune Group, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Replimune Group, Inc. reported earnings per share of -$0.90.
Enterprise value:
578.7M
EV / Invested capital:
1.70x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.19x
EV / Free cash flow:
-2.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$5.2M
Return On Assets:
-61.75%
Net Income Margin (TTM):
--
Return On Equity:
-82.53%
Return On Invested Capital:
-68.62%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.1M | -$3.1M | -$5.2M | -$1M | -$1.6M | |
| Operating Income | -$216.4M | -$233.5M | -$321.8M | -$59.3M | -$84.7M | |
| EBITDA | -$213.3M | -$230.4M | -$316.6M | -$58.3M | -$83M | |
| Diluted EPS | -$3.20 | -$3.12 | -$3.61 | -$0.68 | -$0.90 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $444.4M | $379.4M | $508.2M | $442.6M | $333.7M | |
| Total Assets | $503.5M | $436.1M | $562.4M | $498.2M | $389.5M | |
| Current Liabilities | $16.6M | $23.5M | $39.8M | $43.8M | $52.9M | |
| Total Liabilities | $46.1M | $52M | $97.2M | $116.7M | $126.1M | |
| Total Equity | $457.4M | $384.1M | $465.2M | $381.5M | $263.3M | |
| Total Debt | $31.9M | $31.1M | $59.6M | $74.9M | $75.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$153.6M | -$181.1M | -$262.7M | -$38.6M | -$81.2M | |
| Cash From Investing | -$127.8M | $107.4M | $95.2M | $458K | $84.2M | |
| Cash From Financing | $272.9M | $111.3M | $156M | -$39K | $324K | |
| Free Cash Flow | -$156.6M | -$188.3M | -$269.7M | -$40.7M | -$82.6M | |
REPL
Sector
Market Cap
$826M
$28.4M
Price % of 52-Week High
71.17%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-47.7%
-1.32%
1-Year Price Total Return
-20.05%
-22.19%
Beta (5-Year)
0.659
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.94
200-day SMA
Buy
Level
$8.23
Bollinger Bands (100)
Buy
Level
4.25 - 9.17
Chaikin Money Flow
Buy
Level
13.3M
20-day SMA
Buy
Level
$9.30
Relative Strength Index (RSI14)
Buy
Level
70.77
ADX Line
Buy
Level
32.55
Williams %R
Neutral
Level
-26.4493
50-day SMA
Buy
Level
$7.63
MACD (12, 26)
Buy
Level
0.64
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
284M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2866)
Sell
CA Score
(Annual)
Level (-1.5548)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.6256)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Stock Forecast FAQ
In the current month, REPL has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The REPL average analyst price target in the past 3 months is $12.57.
-
Where Will Replimune Group, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Replimune Group, Inc. share price will rise to $12.57 per share over the next 12 months.
-
What Do Analysts Say About Replimune Group, Inc.?
Analysts are divided on their view about Replimune Group, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Replimune Group, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Replimune Group, Inc.'s Price Target?
The price target for Replimune Group, Inc. over the next 1-year time period is forecast to be $12.57 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is REPL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Replimune Group, Inc. is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of REPL?
You can purchase shares of Replimune Group, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Replimune Group, Inc. shares.
-
What Is The Replimune Group, Inc. Share Price Today?
Replimune Group, Inc. was last trading at $10.52 per share. This represents the most recent stock quote for Replimune Group, Inc.. Yesterday, Replimune Group, Inc. closed at $10.53 per share.
-
How To Buy Replimune Group, Inc. Stock Online?
In order to purchase Replimune Group, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get REPL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
REPL
Sector
P/E ratio
--
23.66x
PEG ratio
-0.19x
-0.01x
P/B ratio
3.14x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
REPL
Sector
Revenue growth
--
4.85%
Earnings growth
-33.88%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.79
-$0.20
Profitability
REPL
Sector
Profitability FY 2024
-$3.5M
$3.6M
Return on invested capital
-68.62%
-30.98%
Return on assets
-61.75%
-27.62%
Return on equity
-82.53%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Feb
5
Balance Sheet
REPL
Sector
Total cash
$323.6M
$27.2M
Short term investments
$372.7M
$25.7M
Total assets
$551.3M
$79.9M
Long term debt
$75.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
